Viatris (VTRS) 44th Annual J.P. Morgan Healthcare Conference summary

Business overview and recent performance

• Operates as three businesses: global generics, established brands, and emerging innovative brands, with $14.1B revenue and $2.2B free cash flow in the last 12 months, serving over 1 billion people annually in 165 countries.

• Achieved strong commercial execution in 2025, advancing five Phase 3 pipeline assets and delivering robust financial results.

• Returned over $1B to shareholders via dividends and buybacks, including quarterly dividends in 2025.

• Completed 60 regional business development deals, including the acquisition of Aculys Pharma in Japan, and prioritized Japan for strategic growth.

• Substantially completed remediation at Indore facility and conducted an enterprise-wide strategic review to drive efficiency and future readiness.

Strategic initiatives and growth outlook

• Anticipates high-value launches in 2026, including sotagliflozin, phentolamine, fast-acting meloxicam, Spidifen, pitolisant, and Effexor GAD in key geographies.

• Enterprise-wide strategic review expected to yield substantial savings and reinvestment opportunities starting in 2026, with benefits extending through 2028.

• Plans to use significant 2026 cash flow for shareholder returns and accretive business development, especially in the U.S. and globally.

• Pipeline milestones and new launches are expected to drive sustainable top- and bottom-line growth from 2026 onward.

• Focused on mid-single digit revenue growth, moving beyond prior periods of revenue and EBITDA decline.

Pipeline and product opportunities

• Five positive Phase 3 results in 2025, with anticipated approvals in 2026; Spidifen launched in Japan, pitolisant filed for narcolepsy and sleep apnea.

• Cenerimod and selatogrel progressing in Phase 3, with full enrollment expected this year; cenerimod targets SLE and lupus nephritis, addressing significant unmet needs.

• Fast-acting meloxicam positioned as a non-opioid acute pain solution, targeting large U.S. market with strong data and 3–5 years of exclusivity, potentially longer with additional patents.

• Selatogrel seen as a paradigm shift for acute MI, leveraging company expertise in rescue medicines and global cardiovascular infrastructure.

• Additional launches include Effexor GAD and low-dose estrogen patch in Japan, and a presbyopia eye care product with anticipated approval this year.